AbbVie (ABBV)
Market Price (5/10/2026): $201.29 | Market Cap: $356.1 BilSector: Health Care | Industry: Biotechnology
AbbVie (ABBV)
Market Price (5/10/2026): $201.29Market Cap: $356.1 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 33% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 31%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 29%, CFO LTM is 19 Bil, FCF LTM is 18 Bil Attractive yieldDividend Yield is 3.3% Stock buyback supportStock Buyback 3Y Total is 4.7 Bil Low stock price volatilityVol 12M is 25% Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Advanced Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -13%, 3Y Excs Rtn is -30% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 38x, P/EPrice/Earnings or Price/(Net Income) is 84x Key risksABBV key risks include [1] the steep decline of Humira sales due to biosimilar competition, Show more. |
| Attractive operating marginsOp Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is 33% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 31%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 29%, CFO LTM is 19 Bil, FCF LTM is 18 Bil |
| Attractive yieldDividend Yield is 3.3% |
| Stock buyback supportStock Buyback 3Y Total is 4.7 Bil |
| Low stock price volatilityVol 12M is 25% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Aging Population & Chronic Disease. Themes include Advanced Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -13%, 3Y Excs Rtn is -30% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 38x, P/EPrice/Earnings or Price/(Net Income) is 84x |
| Key risksABBV key risks include [1] the steep decline of Humira sales due to biosimilar competition, Show more. |
Qualitative Assessment
AI Analysis | Feedback
1. Continued Impact of Humira Biosimilar Erosion: AbbVie's stock has been negatively affected by the ongoing decline in Humira sales due to biosimilar competition. In the first quarter of 2026, global Humira net revenues decreased by 38.6% on a reported basis, or 40.3% operationally, despite strong growth from newer immunology drugs Skyrizi and Rinvoq. This significant erosion of its former top-selling drug has led to investor caution about future growth, even when the company reported stronger-than-expected overall Q1 2026 earnings and raised its full-year guidance, as evidenced by a 4.25% pre-market stock drop on April 29, 2026, following the earnings release.
2. Increased Competition in the Immunology Market: Intensified competition within AbbVie's core immunology franchise contributed to the stock's trend. In early March 2026, the FDA approved rival treatments, including Johnson & Johnson's ICOTYDE, an oral treatment for plaque psoriasis, and Bristol Myers Squibb's Sotyktu for active psoriatic arthritis. These approvals introduced new alternatives for patients and increased competitive pressure on AbbVie's immunology portfolio, including Skyrizi.
Show more
Stock Movement Drivers
Fundamental Drivers
The -9.0% change in ABBV stock from 1/31/2026 to 5/10/2026 was primarily driven by a -48.6% change in the company's P/E Multiple.| (LTM values as of) | 1312026 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 221.18 | 201.29 | -9.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 59,644 | 61,160 | 2.5% |
| Net Income Margin (%) | 4.0% | 6.9% | 72.6% |
| P/E Multiple | 163.8 | 84.3 | -48.6% |
| Shares Outstanding (Mil) | 1,769 | 1,769 | 0.0% |
| Cumulative Contribution | -9.0% |
Market Drivers
1/31/2026 to 5/10/2026| Return | Correlation | |
|---|---|---|
| ABBV | -8.9% | |
| Market (SPY) | 3.6% | 19.4% |
| Sector (XLV) | -6.9% | 46.5% |
Fundamental Drivers
The -6.2% change in ABBV stock from 10/31/2025 to 5/10/2026 was primarily driven by a -16.4% change in the company's P/E Multiple.| (LTM values as of) | 10312025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 214.52 | 201.29 | -6.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 58,328 | 61,160 | 4.9% |
| Net Income Margin (%) | 6.5% | 6.9% | 7.1% |
| P/E Multiple | 100.8 | 84.3 | -16.4% |
| Shares Outstanding (Mil) | 1,768 | 1,769 | -0.1% |
| Cumulative Contribution | -6.2% |
Market Drivers
10/31/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| ABBV | -6.0% | |
| Market (SPY) | 5.5% | 10.3% |
| Sector (XLV) | 0.3% | 52.4% |
Fundamental Drivers
The 6.5% change in ABBV stock from 4/30/2025 to 5/10/2026 was primarily driven by a 8.6% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 188.94 | 201.29 | 6.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 56,334 | 61,160 | 8.6% |
| Net Income Margin (%) | 7.6% | 6.9% | -9.0% |
| P/E Multiple | 78.1 | 84.3 | 7.8% |
| Shares Outstanding (Mil) | 1,769 | 1,769 | 0.0% |
| Cumulative Contribution | 6.5% |
Market Drivers
4/30/2025 to 5/10/2026| Return | Correlation | |
|---|---|---|
| ABBV | 6.7% | |
| Market (SPY) | 30.4% | 16.3% |
| Sector (XLV) | 4.0% | 60.2% |
Fundamental Drivers
The 48.3% change in ABBV stock from 4/30/2023 to 5/10/2026 was primarily driven by a 314.9% change in the company's P/E Multiple.| (LTM values as of) | 4302023 | 5102026 | Change |
|---|---|---|---|
| Stock Price ($) | 135.71 | 201.29 | 48.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 58,054 | 61,160 | 5.4% |
| Net Income Margin (%) | 20.4% | 6.9% | -66.1% |
| P/E Multiple | 20.3 | 84.3 | 314.9% |
| Shares Outstanding (Mil) | 1,771 | 1,769 | 0.1% |
| Cumulative Contribution | 48.3% |
Market Drivers
4/30/2023 to 5/10/2026| Return | Correlation | |
|---|---|---|
| ABBV | 48.5% | |
| Market (SPY) | 78.7% | 21.4% |
| Sector (XLV) | 13.0% | 57.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ABBV Return | 32% | 24% | -0% | 19% | 33% | -10% | 134% |
| Peers Return | 30% | 20% | -3% | 7% | 20% | 4% | 102% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 95% |
Monthly Win Rates [3] | |||||||
| ABBV Win Rate | 75% | 67% | 50% | 67% | 67% | 20% | |
| Peers Win Rate | 55% | 63% | 38% | 47% | 58% | 52% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| ABBV Max Drawdown | -3% | -2% | -16% | 0% | -4% | -12% | |
| Peers Max Drawdown | -7% | -11% | -23% | -10% | -17% | -4% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -7% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: JNJ, PFE, MRK, BMY, LLY. See ABBV Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/8/2026 (YTD)
How Low Can It Go
| Event | ABBV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -13.0% | -18.8% |
| % Gain to Breakeven | 14.9% | 23.1% |
| Time to Breakeven | 11 days | 79 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -13.0% | -6.7% |
| % Gain to Breakeven | 15.0% | 7.1% |
| Time to Breakeven | 30 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -31.5% | -33.7% |
| % Gain to Breakeven | 46.0% | 50.9% |
| Time to Breakeven | 59 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -18.0% | -19.2% |
| % Gain to Breakeven | 22.0% | 23.7% |
| Time to Breakeven | 412 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -12.3% | -3.7% |
| % Gain to Breakeven | 14.1% | 3.9% |
| Time to Breakeven | 10 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -29.8% | -12.2% |
| % Gain to Breakeven | 42.4% | 13.9% |
| Time to Breakeven | 284 days | 62 days |
In The Past
AbbVie's stock fell -13.0% during the 2025 US Tariff Shock. Such a loss loss requires a 14.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ABBV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -31.5% | -33.7% |
| % Gain to Breakeven | 46.0% | 50.9% |
| Time to Breakeven | 59 days | 140 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -29.8% | -12.2% |
| % Gain to Breakeven | 42.4% | 13.9% |
| Time to Breakeven | 284 days | 62 days |
In The Past
AbbVie's stock fell -13.0% during the 2025 US Tariff Shock. Such a loss loss requires a 14.9% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About AbbVie (ABBV)
AI Analysis | Feedback
Like a diversified pharmaceutical giant, similar to Pfizer.
Like Johnson & Johnson, but purely focused on prescription drugs.
AI Analysis | Feedback
- HUMIRA: A therapy administered as an injection for autoimmune and intestinal Behçet's diseases.
- SKYRIZI: Treats moderate to severe plaque psoriasis in adults.
- RINVOQ: A JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis.
- IMBRUVICA: Treats adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
- VENCLEXTA: A BCL-2 inhibitor used to treat adults with CLL or SLL.
- MAVYRET: Treats patients with chronic HCV genotype 1-6 infection.
- CREON: A pancreatic enzyme therapy for exocrine pancreatic insufficiency.
- Synthroid: Used in the treatment of hypothyroidism.
- Linzess/Constella: Treats irritable bowel syndrome with constipation and chronic idiopathic constipation.
- Lupron: Used for advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids.
- Botox therapeutic: A therapeutic product with various medical applications.
- ORILISSA: A nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain.
- Duopa and Duodopa: A levodopa-carbidopa intestinal gel to treat Parkinson's disease.
- Lumigan/Ganfort: Reduces elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
- Ubrelvy: Treats migraine with or without aura in adults.
- Alphagan/Combigan: An alpha-adrenergic receptor agonist for the reduction of intraocular pressure in patients with open angle glaucoma.
- Restasis: A calcineurin inhibitor immunosuppressant to increase tear production.
AI Analysis | Feedback
AbbVie (ABBV) primarily sells its pharmaceutical products to other companies within the healthcare supply chain, rather than directly to individuals. Its major customers are pharmaceutical wholesalers and distributors, who then supply the drugs to pharmacies, hospitals, and other healthcare providers.
The principal customer companies are:
- AmerisourceBergen Corporation (NYSE: ABC)
- Cardinal Health, Inc. (NYSE: CAH)
- McKesson Corporation (NYSE: MCK)
AI Analysis | Feedback
nullAI Analysis | Feedback
```htmlRobert A. Michael, Chairman of the Board and Chief Executive Officer
Robert A. Michael was appointed Chief Executive Officer in 2024 and will assume the additional role of Chairman of the Board effective July 1, 2025. He has more than 30 years of experience, including leadership roles across pharmaceuticals, aesthetics, diagnostics, diabetes care, and nutrition. Prior to becoming CEO, Mr. Michael served as President and Chief Operating Officer of AbbVie. His previous roles at AbbVie also include Vice Chairman and President (2022), Vice Chairman, Finance and Commercial Operations (2021), and Chief Financial Officer (2018). Mr. Michael began his career with Abbott as a member of the financial development program and has been integral to AbbVie's success since its inception, including establishing its first financial planning organization and developing its diversified business strategy. Information regarding founding or managing other companies, selling companies they were previously involved with to an acquirer, or a pattern of managing companies backed by private equity firms is not available.
Scott T. Reents, Executive Vice President, Chief Financial Officer
Scott T. Reents was appointed Senior Vice President, Chief Financial Officer, effective June 23, 2022. He is responsible for the company's global financial operations. Mr. Reents joined Abbott in 2008 and has been with AbbVie since its separation in 2013. Prior to his current role, he served as Vice President, Tax and Treasury (2019-2022) and Vice President, Tax (2013-2019). Before joining Abbott, Mr. Reents worked in finance organizations at Pfizer and Pharmacia, and began his career at Deloitte. Information regarding founding or managing other companies, selling companies they were previously involved with to an acquirer, or a pattern of managing companies backed by private equity firms is not available.
Jeffrey R. Stewart, Executive Vice President, Chief Commercial Officer
Jeffrey R. Stewart serves as Executive Vice President, Chief Commercial Officer, a position he has held since his appointment in 2018. He leads the global commercial organization for AbbVie. Mr. Stewart joined Abbott in 1992 as part of TAP, a former U.S. joint venture with Takeda Chemical Industries. He held various leadership positions in Abbott's U.S. and international pharmaceutical businesses, including Divisional Vice President, Immunology; Divisional Vice President, Primary Care; General Manager, Virology; and General Manager, United Kingdom. Prior to AbbVie's separation from Abbott in 2013, he was Vice President, Abbott Proprietary Pharmaceutical Division, United States.
Azita Saleki-Gerhardt, Ph.D., Executive Vice President, Chief Operations Officer
Dr. Azita Saleki-Gerhardt is Executive Vice President, Chief Operations Officer, responsible for leading a global team in supply and distribution of all AbbVie products, as well as several enterprise services. She joined Abbott in 1993 as a research scientist and held key leadership positions in science and technology and quality assurance. In 2011, she became President, Global Pharmaceutical Operations at Abbott. Following AbbVie's spin-off from Abbott in 2013, Dr. Saleki-Gerhardt was appointed to lead Operations at AbbVie. She has significant experience in complex acquisitions and leading large international business operations.
Roopal Thakkar, M.D., Executive Vice President, Research & Development, Chief Scientific Officer
Dr. Roopal Thakkar was appointed Executive Vice President, Research & Development and Chief Scientific Officer in July 2024. He leads AbbVie's global R&D organization, which includes over 14,000 team members across all phases of discovery and development. A physician by training, Dr. Thakkar joined Abbott/AbbVie in 2003 and has held various positions in clinical development and regulatory affairs. His previous roles include Senior Vice President and Chief Medical Officer for Global Therapeutics, where he led strategic acquisitions and clinical development programs across multiple therapeutic areas.
```AI Analysis | Feedback
```htmlKey Risks to AbbVie (ABBV)
- Humira Biosimilar Erosion: The most significant risk to AbbVie's business is the ongoing and substantial decline in sales of its blockbuster drug, Humira, due to biosimilar competition. Humira's U.S. patent exclusivity ended in 2023, leading to multiple biosimilar launches. The company has experienced significant revenue decreases for Humira, with sales falling by nearly 50% in the first quarter of 2025 and 40% year-over-year in the first three months of 2024 in the U.S.. This "patent cliff" creates considerable margin pressure and necessitates a successful transition to next-generation immunology drugs like Skyrizi and Rinvoq to offset the revenue loss.
- Pipeline Challenges and Long-Term Growth Sustainability: While AbbVie's newer immunology drugs, Skyrizi and Rinvoq, are performing well and are expected to largely replace Humira's revenue, there are concerns about the perceived "lighter" late-stage pipeline compared to its biopharma peers. Many pipeline projects are focused on label expansions rather than entirely new drug approvals, raising questions about the company's ability to sustain long-term growth and find future blockbuster drugs beyond its current immunology and neuroscience portfolios.
- Regulatory and Pricing Pressures: AbbVie faces ongoing threats from evolving regulatory landscapes and market pressures, particularly concerning drug pricing. Cost-containment efforts by governments and private organizations, coupled with potential changes in healthcare policy, such as the Inflation Reduction Act in the U.S., could significantly impact the company's pricing power and revenue streams for its pharmaceutical products.
AI Analysis | Feedback
The entry of biosimilar versions of HUMIRA in the U.S. market represents a clear emerging threat to AbbVie's revenue and market share for its flagship product.
AI Analysis | Feedback
AbbVie (symbol: ABBV) operates in diverse pharmaceutical markets with several key products. The addressable market sizes for its main products or the therapeutic areas they target are detailed below:
- HUMIRA (adalimumab): Used for autoimmune and intestinal Behçet's diseases. The global Humira market size was valued at approximately USD 9.10 billion in 2024. However, due to patent expirations and the entry of biosimilars, the market for branded Humira is projected to decline to about USD 4.11 billion by 2030, with a CAGR of -11.29% from 2025 to 2030. The broader global autoimmune disease therapeutics market was valued at USD 168.6 billion in 2025 and is forecast to reach USD 226.2 billion by 2035. The global autoimmune disease diagnostics market, which indicates the scale of diagnosed patients, was estimated at USD 6.07 billion in 2025 and is projected to reach USD 9.58 billion by 2033.
- SKYRIZI: Treats moderate to severe plaque psoriasis in adults. The global psoriasis treatment market was estimated at USD 28.1 billion in 2024 and is expected to grow to USD 68.4 billion by 2034. Another source indicates the global psoriasis market size was valued at USD 31.68 billion in 2024 and is projected to reach USD 64.06 billion by 2032. North America accounted for the largest revenue share in the psoriasis treatment market in 2025.
- RINVOQ: A JAK inhibitor for moderate to severe active rheumatoid arthritis. The global rheumatoid arthritis therapeutics market size was estimated at USD 25.76 billion in 2024 and is projected to reach USD 41.42 billion by 2033. Another estimate valued the global rheumatoid arthritis drugs market at USD 60 billion, based on a five-year historical analysis. North America dominated the rheumatoid arthritis therapeutics market with the largest revenue share of 52.21% in 2024.
- IMBRUVICA / VENCLEXTA: These are used for conditions like chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Market sizes specific to these individual products or their direct addressable markets (CLL/SLL treatment market) were not explicitly found in the search results.
- MAVYRET: Treats chronic HCV genotype 1-6 infection. The global hepatitis C market size accounted for USD 7.95 billion in 2024 and is anticipated to reach around USD 10.62 billion by 2034. Another report valued the global hepatitis C market at USD 18.0 billion in 2023, expecting it to reach USD 47.1 billion by 2034. North America led the global market with the highest market share in 2024.
- CREON: A pancreatic enzyme therapy for exocrine pancreatic insufficiency (EPI). The global exocrine pancreatic insufficiency market size was valued at USD 3.2 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 6.6% from 2024 to 2030. Another source states the global exocrine pancreatic insufficiency therapeutics market size was USD 2.55 billion in 2026 and is projected to reach USD 3.51 billion by 2034. North America dominated the market in 2023.
- Synthroid: Used in the treatment of hypothyroidism. Market size information for Synthroid or the hypothyroidism treatment market was not explicitly found in the search results.
- Linzess/Constella: Treats irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Market size information for these products or their specific addressable markets was not explicitly found in the search results.
- Lupron: For the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. Market size information specific to Lupron or its diverse indications was not explicitly found in the search results.
- Botox therapeutic: The global botulinum toxin market, which includes therapeutic applications, was estimated at USD 13.2 billion in 2025 and is projected to reach USD 27.9 billion by 2033. Therapeutic applications held approximately 60% of the global market share in 2023. North America leads the global market, holding over 46.9% of the revenue share in 2023. The global therapeutic neurotoxin market size was valued at USD 6.34 billion in 2025 and is projected to reach USD 13.39 billion by 2034.
- ORILISSA: A nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. Market size information specific to Orilissa or the endometriosis pain market was not explicitly found in the search results.
- Duopa and Duodopa: Levodopa-carbidopa intestinal gel to treat Parkinson's disease. The global Parkinson's disease treatment market size was estimated at USD 5.65 billion in 2024 and is expected to reach USD 7.58 billion by 2030. Another source states the global Parkinson's disease drugs market size is likely to be valued at US$ 7.6 billion in 2025 and is estimated to reach US$ 13.3 billion in 2032. North America Parkinson's Disease Drugs Market is anticipated to account for approximately 45.6% of the share in 2025.
- Lumigan/Ganfort / Alphagan/Combigan: These ophthalmic solutions are for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension. Market size information for these specific products or the glaucoma/ocular hypertension market was not explicitly found in the search results.
- Ubrelvy: Treats migraine with or without aura in adults. The global migraine market size was valued at USD 3.95 billion in 2024 and is projected to reach USD 5.45 billion by 2032. Another estimate for the global migraine market size is expected to be worth around US$ 6.95 billion in 2024 and projected to reach US$ 18.86 billion by 2034. North America led the migraine market in 2024, achieving over 42.5% share. The migraine market across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) is poised to grow from $9.2 billion in 2023 to $16.4 billion in 2033.
- Restasis: A calcineurin inhibitor immunosuppressant to increase tear production (for dry eye). The global dry eye disease market size was estimated to be valued at USD 7.33 billion in 2024 and is expected to surpass USD 13.26 billion by 2031. Other estimates for the global dry eye syndrome treatment market size include USD 6.29 billion in 2024, projected to reach USD 9.20 billion by 2030, and USD 5.0 billion in 2024, expected to reach USD 8.0 billion by 2033. North America currently dominates the market, holding a significant market share of over 55.0% in 2024.
AI Analysis | Feedback
AbbVie (ABBV) anticipates several key drivers for future revenue growth over the next two to three years, building upon its diversified portfolio and pipeline investments.
Here are 5 expected drivers of AbbVie's future revenue growth:
- Strong Performance of Immunology Drugs (Skyrizi and Rinvoq): AbbVie expects its next-generation immunology drugs, Skyrizi and Rinvoq, to be the primary growth engines, significantly offsetting the impact of Humira's biosimilar erosion. These drugs are approved for major indications previously covered by Humira, as well as new areas like atopic dermatitis and inflammatory bowel disease. The combined sales of Skyrizi and Rinvoq are projected to exceed $31 billion in 2026, surpassing earlier long-term guidance.
- Growth in the Neuroscience Franchise: The neuroscience portfolio is poised for substantial expansion, with key products such as Vraylar, Botox Therapeutic, and the recently launched Vyalev. Vyalev is expected to achieve blockbuster status in 2026, contributing to the neuroscience franchise's anticipated global sales of $12.5 billion in the same year. Oral CGRP inhibitors like Ubrelvy and Qulipta, used for migraine treatment, are also forecast to surpass $5 billion in peak sales.
- Expansion and Development in Oncology: Despite near-term challenges for Imbruvica due to pricing changes from the Inflation Reduction Act, AbbVie is actively strengthening its oncology segment. The company's portfolio includes newer assets like Epkinly and Elahere, and it continues to invest in strategic acquisitions and pipeline developments, including bispecific antibodies and antibody-drug conjugates (ADCs). These efforts are expected to contribute multi-billion incremental revenue to the oncology franchise between 2026 and 2028.
- Rebound in the Aesthetics Business: The aesthetics segment, notably driven by products such as Botox, is anticipated to experience a rebound in sales. Management expects high single-digit growth for Botox Therapeutic sales in 2026, contributing positively to the company's overall revenue.
- Strategic Acquisitions and Robust Pipeline Investment: AbbVie's ongoing commitment to research and development (R&D) and opportunistic strategic acquisitions are crucial for long-term growth and diversification. The company has invested significantly in new business development, including platforms for CAR T therapy, next-generation psychedelics, novel trispecific antibodies, and treatments for obesity, ensuring a robust pipeline that extends growth beyond existing assets.
AI Analysis | Feedback
Share Repurchases
- AbbVie repurchased $1.6 billion in shares in 2023, $1.1 billion in 2022, and $1.3 billion in 2024.
- On February 16, 2023, AbbVie's board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization, bringing the total authorization to $20.0 billion.
- The remaining stock repurchase authorization was $3.5 billion as of December 31, 2024.
Share Issuance
- AbbVie's shares outstanding were 1.773 billion in 2024, showing a 0% decline from 2023.
- The number of shares outstanding was 1,765,537 thousand in 2023, 1,767,880 thousand in 2022, and 1,767,880 thousand in 2021.
Outbound Investments
- AbbVie acquired ImmunoGen for $10.1 billion in February 2024 (agreement in November 2023) to strengthen its oncology portfolio and accelerate its entry into the ovarian cancer treatment market.
- The company acquired Cerevel Therapeutics for $8.7 billion in August 2024 (agreement in December 2023) to significantly strengthen its neuroscience pipeline.
- AbbVie acquired Capstan Therapeutics for approximately $2.1 billion in July 2025, adding a potential first-in-class in vivo tLNP anti-CD19 CAR-T therapy to its immunology pipeline and Capstan's proprietary tLNP platform technology.
Capital Expenditures
- AbbVie's capital expenditures were $1.214 billion in 2025, $974 million in 2024, $777 million in 2023, $695 million in 2022, and $787 million in 2021.
- The company made a significant investment in U.S. manufacturing capabilities.
- AbbVie announced in January 2026 a deal with the Trump administration to invest $100 billion in its U.S. operations over the next 10 years.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| AbbVie Earnings Notes | 04/28/2026 | |
| 5-Day Sell-Off Sends AbbVie Stock Down 7.5% | 03/24/2026 | |
| Can United Therapeutics Outrun AbbVie in the Next Rally? | 03/19/2026 | |
| What Could Spark the Next Big Move In AbbVie Stock | 01/06/2026 | |
| How Does AbbVie Stock Stack Up Against Its Peers? | 01/06/2026 | |
| How Low Can AbbVie Stock Really Go? | 01/06/2026 | |
| ARTICLES | ||
| How Will AbbVie Stock React To Its Upcoming Earnings? | 04/28/2026 | |
| AbbVie Stock Slides -7.5% With A 5-Day Losing Spree | 03/24/2026 | |
| What’s Happening With AbbVie Stock? | 03/19/2026 | |
| United Therapeutics or AbbVie: Which Stock Has More Upside? | 03/19/2026 | |
| Where Could The Next Breakout for AbbVie Stock Come From | 01/06/2026 |
Trade Ideas
Select ideas related to ABBV.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
| 04302022 | ABBV | AbbVie | Quality | Q | Momentum | UpsideQuality Stocks with Momentum and UpsideBuying quality stocks with strong momentum but still having room to run | 2.5% | 6.9% | -7.8% |
| 10312018 | ABBV | AbbVie | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 3.9% | 8.0% | -15.8% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 156.31 |
| Mkt Cap | 315.6 |
| Rev LTM | 64,541 |
| Op Inc LTM | 17,800 |
| FCF LTM | 13,012 |
| FCF 3Y Avg | 13,283 |
| CFO LTM | 18,460 |
| CFO 3Y Avg | 15,811 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.4% |
| Rev Chg 3Y Avg | 3.2% |
| Rev Chg Q | 7.6% |
| QoQ Delta Rev Chg LTM | 1.7% |
| Op Inc Chg LTM | 44.8% |
| Op Inc Chg 3Y Avg | 44.2% |
| Op Mgn LTM | 27.4% |
| Op Mgn 3Y Avg | 22.9% |
| QoQ Delta Op Mgn LTM | -0.4% |
| CFO/Rev LTM | 27.3% |
| CFO/Rev 3Y Avg | 27.1% |
| FCF/Rev LTM | 19.8% |
| FCF/Rev 3Y Avg | 21.0% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 315.6 |
| P/S | 4.9 |
| P/Op Inc | 19.2 |
| P/EBIT | 20.7 |
| P/E | 28.1 |
| P/CFO | 17.0 |
| Total Yield | 6.3% |
| Dividend Yield | 3.1% |
| FCF Yield 3Y Avg | 5.4% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.7% |
| 3M Rtn | -8.3% |
| 6M Rtn | 14.3% |
| 12M Rtn | 28.5% |
| 3Y Rtn | 27.0% |
| 1M Excs Rtn | -13.5% |
| 3M Excs Rtn | -15.0% |
| 6M Excs Rtn | 6.2% |
| 12M Excs Rtn | -8.0% |
| 3Y Excs Rtn | -55.0% |
Comparison Analyses
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA217906 | EMBLAVEO | avibactam sodium | powder | 2072025 | -2.3% | 5.8% | 21.2% | 10.2% | 10.2% |
| NDA216962 | VYALEV | foscarbidopa | solution | 10162024 | -9.2% | -8.2% | 23.3% | 11.3% | 11.3% |
| NDA218347 | RINVOQ LQ | upadacitinib | solution | 4262024 | 17.1% | 19.7% | 20.8% | 33.2% | 35.1% |
| NDA214028 | VUITY | pilocarpine hydrochloride | solution/drops | 10282021 | 25.3% | 45.2% | 39.8% | 36.9% | 116.6% |
| NDA215206 | QULIPTA | atogepant | tablet | 9282021 | 26.7% | 54.5% | 40.2% | 53.6% | 124.0% |
| NDA215110 | MAVYRET | glecaprevir | pellets | 6102021 | -6.7% | 9.3% | 28.5% | 28.8% | 109.2% |
| NDA213388 | ORIAHNN (COPACKAGED) | elagolix sodium,estradiol,norethindrone acetate | capsule | 5292020 | 2.9% | 16.1% | 28.3% | 77.3% | 175.6% |
| NDA211911 | DURYSTA | bimatoprost | implant | 3042020 | 0.5% | 5.2% | 21.3% | 80.9% | 182.5% |
| NDA211765 | UBRELVY | ubrogepant | tablet | 12232019 | -27.6% | 10.9% | 20.2% | 61.8% | 191.1% |
| NDA211675 | RINVOQ | upadacitinib | tablet, extended release | 8162019 | 39.6% | 50.1% | 55.9% | 100.4% | 313.7% |
| ... | |||||||||
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Skyrizi | 11,718 | 7,763 | 5,165 | 2,939 | 1,590 |
| Humira | 8,993 | 14,404 | 21,237 | 20,694 | 19,832 |
| Rinvoq | 5,971 | 3,969 | 2,522 | 1,651 | 731 |
| Imbruvica | 3,347 | 3,596 | 4,568 | 5,408 | 5,314 |
| Botox Therapeutic | 3,283 | 2,991 | 2,719 | 2,451 | 1,387 |
| Vraylar | 3,267 | 2,759 | 2,038 | 1,728 | 951 |
| All other | 3,032 | 3,035 | 4,137 | 5,019 | 2,923 |
| Botox Cosmetic | 2,720 | 2,682 | 2,615 | 2,232 | 1,112 |
| Venclexta | 2,583 | 2,288 | 2,009 | 1,820 | 1,337 |
| Creon | 1,383 | 1,268 | 1,278 | 1,191 | 1,114 |
| Mavyret | 1,311 | 1,430 | 1,541 | 1,710 | 1,830 |
| Other Aesthetics | 1,279 | 1,234 | 1,290 | 1,466 | 760 |
| Juvederm Collection | 1,177 | 1,378 | 1,428 | 1,535 | 718 |
| Other Eye Care | 1,071 | 803 | 747 | 1,169 | 693 |
| Ubrelvy | 1,006 | 815 | 680 | 552 | 125 |
| Linzess/Constella | 954 | 1,108 | 1,035 | 1,038 | 667 |
| Qulipta | 658 | 408 | 158 | ||
| Ozurdex | 494 | 472 | 428 | ||
| Elahere | 479 | 0 | |||
| Duodopa | 447 | 468 | 458 | 511 | 494 |
| Lumigan/Ganfort | 429 | 432 | 514 | 579 | 378 |
| Alphagan/Combigan | 248 | 272 | 346 | 529 | 326 |
| Other Neuroscience | 239 | 276 | 475 | 685 | 539 |
| Epkinly | 146 | 31 | 0 | ||
| Vyalev | 99 | ||||
| Other Oncology | 0 | ||||
| Restasis | 436 | 666 | 1,290 | 787 | |
| Lo Loestrin | 356 | ||||
| Lupron | 752 | ||||
| Orilissa/Oriahnn | 125 | ||||
| Other Women's Health | 192 | ||||
| Synthroid | 771 | ||||
| Total | 56,334 | 54,318 | 58,054 | 56,197 | 45,804 |
Price Behavior
| Market Price | $201.55 | |
| Market Cap ($ Bil) | 356.5 | |
| First Trading Date | 01/02/2013 | |
| Distance from 52W High | -15.6% | |
| 50 Days | 200 Days | |
| DMA Price | $211.18 | $215.19 |
| DMA Trend | up | down |
| Distance from DMA | -4.6% | -6.3% |
| 3M | 1YR | |
| Volatility | 25.8% | 24.6% |
| Downside Capture | 0.22 | 0.12 |
| Upside Capture | -9.82 | 30.10 |
| Correlation (SPY) | 17.6% | 14.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.56 | 0.51 | 0.31 | 0.16 | 0.32 | 0.33 |
| Up Beta | 1.24 | 1.02 | 0.88 | 0.55 | 0.63 | 0.39 |
| Down Beta | -5.50 | 0.13 | -0.33 | -0.35 | -0.10 | 0.46 |
| Up Capture | -23% | -8% | 4% | 2% | 22% | 8% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 10 | 18 | 30 | 62 | 129 | 396 |
| Down Capture | 262% | 100% | 52% | 37% | 43% | 37% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 12 | 25 | 34 | 63 | 122 | 356 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ABBV | |
|---|---|---|---|---|
| ABBV | 10.7% | 24.7% | 0.36 | - |
| Sector ETF (XLV) | 7.9% | 15.4% | 0.30 | 58.8% |
| Equity (SPY) | 29.0% | 12.5% | 1.83 | 14.1% |
| Gold (GLD) | 39.8% | 27.0% | 1.22 | 4.8% |
| Commodities (DBC) | 50.6% | 18.0% | 2.21 | -20.1% |
| Real Estate (VNQ) | 13.0% | 13.5% | 0.66 | 27.6% |
| Bitcoin (BTCUSD) | -17.4% | 42.1% | -0.34 | 1.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ABBV | |
|---|---|---|---|---|
| ABBV | 16.2% | 22.8% | 0.62 | - |
| Sector ETF (XLV) | 4.9% | 14.6% | 0.16 | 57.1% |
| Equity (SPY) | 12.8% | 17.1% | 0.59 | 25.5% |
| Gold (GLD) | 20.9% | 17.9% | 0.95 | 3.9% |
| Commodities (DBC) | 13.8% | 19.1% | 0.59 | 3.6% |
| Real Estate (VNQ) | 3.4% | 18.8% | 0.08 | 28.4% |
| Bitcoin (BTCUSD) | 7.0% | 56.0% | 0.34 | 0.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ABBV | |
|---|---|---|---|---|
| ABBV | 17.4% | 25.8% | 0.65 | - |
| Sector ETF (XLV) | 9.3% | 16.5% | 0.46 | 63.1% |
| Equity (SPY) | 15.1% | 17.9% | 0.72 | 42.6% |
| Gold (GLD) | 13.4% | 15.9% | 0.69 | 0.3% |
| Commodities (DBC) | 9.3% | 17.8% | 0.44 | 12.8% |
| Real Estate (VNQ) | 5.8% | 20.7% | 0.24 | 35.5% |
| Bitcoin (BTCUSD) | 67.8% | 66.9% | 1.07 | 3.9% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 4/3/2026 | -1.0% | -0.4% | |
| 1/7/2026 | -4.0% | -4.9% | -3.5% |
| 10/3/2025 | -1.6% | -1.5% | -8.7% |
| 7/3/2025 | -0.9% | 1.7% | 5.1% |
| 4/3/2025 | -7.3% | -13.6% | -1.9% |
| 1/6/2025 | -0.3% | -2.5% | 8.2% |
| 10/3/2024 | -0.6% | -0.6% | 5.0% |
| 7/3/2024 | 2.1% | 3.7% | 16.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 8 | 11 | 14 |
| # Negative | 17 | 14 | 10 |
| Median Positive | 1.6% | 2.5% | 7.2% |
| Median Negative | -1.3% | -2.4% | -5.9% |
| Max Positive | 5.5% | 16.1% | 29.6% |
| Max Negative | -7.3% | -13.6% | -12.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/20/2026 | 10-K |
| 09/30/2025 | 11/04/2025 | 10-Q |
| 06/30/2025 | 08/04/2025 | 10-Q |
| 03/31/2025 | 05/09/2025 | 10-Q |
| 12/31/2024 | 02/14/2025 | 10-K |
| 09/30/2024 | 11/04/2024 | 10-Q |
| 06/30/2024 | 08/07/2024 | 10-Q |
| 03/31/2024 | 05/03/2024 | 10-Q |
| 12/31/2023 | 02/20/2024 | 10-K |
| 09/30/2023 | 11/06/2023 | 10-Q |
| 06/30/2023 | 08/07/2023 | 10-Q |
| 03/31/2023 | 05/05/2023 | 10-Q |
| 12/31/2022 | 02/17/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/04/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q1 2026 Earnings Reported 4/29/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Adjusted Diluted EPS | 14.1 | 14.2 | 14.3 | -2.0% | Lowered | Guidance: 14.5 for 2026 | |
Prior: Q4 2025 Earnings Reported 2/4/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Adjusted Diluted EPS | 14.4 | 14.5 | 14.6 | 36.1% | Higher New | Actual: 10.6 for 2025 | |
| 2026 Dividend Increase | 0.06 | ||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Purdue, David Ryan | SVP, Controller | Direct | Sell | 3062026 | 233.56 | 5,230 | 1,221,519 | 619,868 | Form |
| 2 | Siatis, Perry C | EVP, GC AND SECRETARY | Direct | Sell | 3032026 | 234.39 | 18,668 | 4,375,549 | 1,082,637 | Form |
| 3 | Siatis, Perry C | EVP, GC AND SECRETARY | Direct | Sell | 2272026 | 230.00 | 22,381 | 5,147,630 | 8,771,510 | Form |
| 4 | Saleki-Gerhardt, Azita | EVP, CHIEF OPERATIONS OFFICER | Direct | Sell | 8142025 | 198.42 | 42,370 | 8,407,055 | 35,178,279 | Form |
| 5 | Donoghoe, Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Direct | Sell | 8072025 | 198.51 | 13,295 | 2,639,253 | 11,562,738 | Form |
ABBV Trade Sentinel
OVERWEIGHT (Score 9-10)
CONVICTION RATIONALE
The analysis yields a probability-adjusted skew greater than 2.0x (3.89x). This is driven by the high probability (70%) assigned to the upside case, which is justified by management's demonstrated history of excellent execution in the critical post-Humira product transition and a widening competitive moat in the most important customer segment. The downside, while significant, is viewed as less likely than continued successful execution, leading to an OVERWEIGHT rating.
STOCK ARCHETYPE
Mature Cash CowAbbVie is a large, highly profitable biopharmaceutical company that generates substantial free cash flow, pays a significant dividend, and is focused on capital efficiency. While it has strong growth assets, its core challenge is managing the lifecycle of its massive portfolio, particularly the transition from the Humira era, which fits the 'Mature Cash Cow' archetype's focus on capital efficiency and pricing power.
INVESTMENT THESIS
The core long thesis is AbbVie's successful pivot from its legacy blockbuster Humira to its next-generation immunology drugs, Skyrizi and Rinvoq. This transition is not merely replacing revenue but actively driving top-line growth and, more importantly, a significant expansion in operating margins as guided by management.
- The ex-Humira growth platform delivered 14.5% reported growth in Q4 2025, with Skyrizi sales up 32.5% and Rinvoq up 29.5%.
- Management is guiding for an aggressive expansion of adjusted operating margin to approximately 48.5% in 2026.
- AbbVie projects high single-digit revenue growth through 2029, providing long-term visibility into the durability of this new portfolio.
- The company has secured dominant formulary access for Skyrizi, with a 45% total prescription share in the US biologics psoriasis market and capture rates exceeding 55%.
PRIMARY RISK
The primary risk is that the growth rates of Skyrizi and Rinvoq, while still high, are decelerating faster than the market expects, and that access to these drugs could be threatened by payers. This could jeopardize the revenue and margin expansion central to the thesis.
- Both Skyrizi's (+31.9%) and Rinvoq's (+28.6%) YoY growth rates showed a marked deceleration in Q4 2025 compared to prior quarters.
- Rinvoq's sales have missed consensus estimates for two consecutive quarters, indicating potential execution or competitive issues.
- A major drug list administrator removed both Skyrizi and Rinvoq from its formulary for certain conditions, effective January 1, 2026, setting a negative precedent.
| KPI | Threshold | Rationale |
|---|---|---|
| Rinvoq Quarterly Revenue | Meet or Exceed Analyst Consensus | After two consecutive misses, another failure to meet expectations would confirm a structural issue with this key growth pillar, severely damaging the bull thesis. |
| Skyrizi YoY Growth Rate | >25% YoY | While deceleration is expected, the growth rate must remain robust. A drop below this level would signal a faster-than-expected maturation or competitive intrusion, threatening long-term growth forecasts. |
| 2027 PBM Formulary Announcements | No new major net exclusions for Skyrizi/Rinvoq | This is the most critical external catalyst. Maintaining broad, preferred access is the bottleneck for the entire volume-driven growth story. A negative announcement would be a thesis-killer. |
Growth Engine Durability: Decelerating Stars vs. Emerging Threats
BULL VIEW
The growth duo remains a dominant force, capturing significant market share with superior formulary access. Their continued expansion will more than offset Humira's erosion and other portfolio weaknesses.
CORE TENSION
Can the impressive, but decelerating, growth of Skyrizi and Rinvoq overcome increasing payer pushback and competitive pressure, ensuring they successfully replace Humira's lost earnings power?
PREVAILING SENTIMENT
The core operational health verdict is 'WEAKENING' due to sequentially decelerating YoY growth rates for both Skyrizi (+31.9% in Q4 vs. +46.0% in Q3) and Rinvoq (+28.6% in Q4 vs. +34.1% in Q3).
BEAR VIEW
Sequential growth deceleration in both key drugs, coupled with formulary exclusions and Rinvoq's consensus misses, signals a peak growth rate and intensifying future headwinds.
| Timeline | Event & Metric To Watch |
|---|---|
Late April 2026 | Q1 2026 Earnings Call Watch: Sequential growth rate of Skyrizi and Rinvoq. Any stabilization or re-acceleration would be a significant positive, while further deceleration confirms the bear case. |
Anytime (H1 2026) | PBM Formulary Updates for 2027 Watch: Announcements from major PBMs (e.g., Express Scripts, CVS Caremark) regarding the formulary status of Skyrizi and Rinvoq for 2027. |
By March 2026 | CMS IRA Price Negotiation Precedent Watch: The magnitude of discounts CMS publishes for the 2027 negotiated drugs. Discounts >50% on drugs in similar therapeutic classes would be a negative signal. |
Anytime (H1 2026) | Unexpected Late-Stage Pipeline Readout Watch: Press release announcing top-line results from a Phase 3 trial, particularly for a high-potential asset in oncology or neuroscience. |
| Date | Event | Stock Impact |
|---|---|---|
2025-10-31 | Q3 2025 Earnings Report Details: The company reported third-quarter results that beat analyst estimates and raised its annual profit guidance, driven by strong demand for its immunology drugs. [2, 8] | Fell notably by -4.45% $226.37 -> $216.29 |
2025-11-18 | FDA Approval for Epkinly in Follicular Lymphoma Details: Received FDA approval for Epkinly to treat relapsed or refractory follicular lymphoma, marking the third indication for the co-developed cancer drug. [11] | Changed Little (-0.06%) $232.13 -> $232.00 |
2026-01-12 | Strategic Licensing and Manufacturing Deals Details: Announced an exclusive licensing deal with RemeGen for a cancer antibody and the acquisition of a new manufacturing facility in Arizona, signaling strategic growth initiatives. [5] | Changed Little (-0.02%) $220.08 -> $220.04 |
2026-01-16 | Epcoritamab (Epkinly) Phase 3 Topline Results Details: AbbVie announced positive topline results for its cancer drug Epkinly in DLBCL, showing improved progression-free survival, though it did not show a statistically significant improvement in overall survival. [5, 13] | Slight -1.11% pullback $216.75 -> $214.35 |
2026-02-03 | FDA/EMA Applications for Rinvoq in Vitiligo Details: AbbVie submitted applications for Rinvoq to treat vitiligo, a potential label expansion for a key growth driver, indicating pipeline progress. [19] | Flat (0.01%) $225.64 -> $225.66 |
2026-02-04 | Q4 2025 Earnings and FY 2026 Guidance Details: Despite beating revenue and EPS estimates, the stock sold off on concerns over decelerating growth in key products and a weaker-than-expected performance from Rinvoq. [2, 3] | Fell notably by -3.79% $225.66 -> $217.11 |
Position Sizing
1% - 3%
CONSERVATIVE
The stock is in a Moderate Volatility regime. However, the Bearish sentiment, driven by decelerating growth and formulary risk, combined with a high valuation, reduces conviction and warrants a Conservative sizing.
Diversification Alternatives
UTHR
INDUSTRYUTHR exhibits accelerating revenue growth and expanding operating margins over a five-year period, contrasting with ABBV's decelerating growth and portfolio pressures. [15]
AMGN
INDUSTRYWhile a direct competitor, AMGN provides a different risk profile. It serves as a good alternative for investors seeking large-cap pharma exposure but wanting to avoid ABBV's specific growth deceleration issues.
AbbVie is successfully re-rating from a single-product story dependent on Humira to a diversified pharmaceutical leader, driven by the rapid, market-share-capturing growth of its next-generation immunology drugs, Skyrizi and Rinvoq.
Filter all news through the lens of the post-Humira growth narrative: Is AbbVie's ex-Humira portfolio, led by Skyrizi and Rinvoq, growing fast enough to exceed expectations and drive margin expansion?
Skyrizi and Rinvoq combined revenues growing >20% YoY; any upward revision to 2026+ guidance for Skyrizi/Rinvoq; positive late-stage clinical data for pipeline assets in immunology or neuroscience; market share gains for Skyrizi and Rinvoq in inflammatory bowel disease (IBD). [8, 26]
Slower than expected growth or market share erosion for Skyrizi or Rinvoq; faster than guided revenue decline for Humira [30]; significant clinical trial failures in the late-stage pipeline; new competitive drug launches that challenge Skyrizi/Rinvoq's efficacy or safety profile.
Quarterly fluctuations in Humira revenue (the decline is expected and modeled); minor pipeline updates for early-stage assets; competitor announcements for drugs in different therapeutic classes; general macroeconomic commentary.
Repricing Catalyst
The primary catalyst is the market's realization that the combination of Skyrizi and Rinvoq is not just replacing Humira's lost revenue but is on track to become a larger, more durable franchise. Management guided for the pair to exceed $31.5 billion in 2026, surpassing the previous 2027 long-term target and Humira's peak sales, driving a projected 45% EPS surge in 2026. [8, 26, 31]
Immunology (Skyrizi, Rinvoq, Humira)
$30.4B TTM (50% of Total) · 83% MarginWhat It Is
Skyrizi (risankizumab) for psoriasis and inflammatory bowel disease; Rinvoq (upadacitinib) for rheumatoid arthritis and other inflammatory conditions; Humira (adalimumab) for a wide range of autoimmune diseases.
Who Pays & How
Major drug wholesalers (e.g., Cencora, Cardinal Health, McKesson) pay to distribute drugs to pharmacies to fill prescriptions. Payment is non-discretionary due to patient need and doctor prescriptions, protected by strong patent estates and clinical data.
Competition
Neuroscience (Botox Therapeutic, Vraylar, Migraine)
$10.8B TTM (18% of Total) · 83% MarginWhat It Is
Botox Therapeutic for migraines and movement disorders; Vraylar (cariprazine) for bipolar disorder and schizophrenia; Ubrelvy (ubrogepant) for acute migraine treatment; Qulipta (atogepant) for migraine prevention.
Who Pays & How
Wholesalers and specialty distributors pay to supply hospitals, clinics, and pharmacies. Use is driven by physician prescriptions for chronic neurological and psychiatric conditions.
Competition
Oncology (Imbruvica, Venclexta)
$6.7B TTM (11% of Total) · 83% MarginWhat It Is
Imbruvica (ibrutinib) and Venclexta (venetoclax) for various blood cancers; Elahere for ovarian cancer.
Who Pays & How
Specialty pharmacies and wholesalers pay to provide these targeted cancer therapies prescribed by oncologists for specific, life-threatening diseases.
Competition
Aesthetics (Botox Cosmetic, Juvederm)
$4.9B TTM (8% of Total) · 83% MarginWhat It Is
Botox Cosmetic, a neurotoxin for reducing facial wrinkles; The Juvederm Collection, a line of hyaluronic acid dermal fillers.
Who Pays & How
Physicians (dermatologists, plastic surgeons) and medical spas pay for products used in elective, cash-pay cosmetic procedures.
Competition
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.